Form 4: C4 Therapeutics Director Kenneth Anderson Acquires Shares in Lieu of Cash Compensation

Director Kenneth Anderson acquired 7,841 shares of C4 Therapeutics common stock in lieu of cash compensation, according to a recent SEC filing.

Summary

• Kenneth Carl Anderson, a director of C4 Therapeutics, acquired 7,841 shares of common stock on April 1, 2025.
• The shares were received in lieu of cash compensation for services as a non-employee director, as per the Issuer's Non-Employee Director Compensation Policy.
• The price per share was $1.435, based on the closing market price of C4 Therapeutics' common stock on April 1, 2025.
• Following the transaction, Anderson directly owns 127,609 shares.
• Anderson also has indirect ownership through various trusts and his spouse.
• He disclaims beneficial ownership of shares held by the Kenneth C. Anderson 2016 Grantor Retained Annuity Trust, the Cynthia E. Anderson 2016 Grantor Retained Annuity Trust, the Kenneth C. Anderson 2015 Irrevocable Trust, and the Cynthia E. Anderson 2015 Irrevocable Trust, except to the extent of his pecuniary interest therein.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director taking shares in lieu of cash suggests confidence in the company's future, but it's a standard compensation practice.

Positives

• Director's confidence in the company is demonstrated by accepting shares in lieu of cash.
• The acquisition increases the director's alignment with shareholder interests.

Industry Context

This type of transaction, where directors receive shares as part of their compensation, is common in the biotech industry to align management interests with those of shareholders. It's a standard practice to conserve cash, especially for companies still in the development stage.

Comparison to Industry Standards

• Many biotech companies, such as Amgen and Gilead, offer stock options and restricted stock units to their directors and executives as part of their compensation packages.
• The specific amount and terms of these equity grants vary depending on the company's size, stage of development, and compensation philosophy.
• Compared to industry benchmarks, the decision to take shares in lieu of cash is not unusual for directors in similar positions.

Stakeholder Impact

• Shareholders may view the director's decision to take shares as a positive sign of alignment with their interests.
• Employees may see it as a sign of the company's commitment to conserving cash.

Key Dates

Keywords

C4 Therapeutics, Director, Share Acquisition, Form 4, CCCC, Compensation, Kenneth Anderson